Bernard Arulanandam to Spleen
This is a "connection" page, showing publications Bernard Arulanandam has written about Spleen.
Connection Strength
0.985
-
Ainsworth S, Ketter PM, Yu JJ, Grimm RC, May HC, Cap AP, Chambers JP, Guentzel MN, Arulanandam BP. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection. Vaccine. 2017 06 08; 35(26):3387-3394.
Score: 0.141
-
Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
Score: 0.131
-
Rodriguez AR, Plascencia-Villa G, Witt CM, Yu JJ, Jos?-Yacam?n M, Chambers JP, Perry G, Guentzel MN, Arulanandam BP. Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cell Immunol. 2015 Jun; 295(2):83-91.
Score: 0.122
-
Kamalakaran S, Chaganty BK, Gupta R, Guentzel MN, Chambers JP, Murthy AK, Arulanandam BP. Vaginal chlamydial clearance following primary or secondary infection in mice occurs independently of TNF-a. Front Cell Infect Microbiol. 2013; 3:11.
Score: 0.106
-
Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010 Mar 08; 28(11):2323-9.
Score: 0.085
-
Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
Score: 0.082
-
Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
Score: 0.080
-
Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
Score: 0.075
-
Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
Score: 0.042
-
Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21; 17(3):252-60.
Score: 0.040
-
Arulanandam BP, Van Cleave VH, Metzger DW. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol. 1999 01; 29(1):256-64.
Score: 0.040
-
Manam S, Chaganty BK, Evani SJ, Zafiratos MT, Ramasubramanian AK, Arulanandam BP, Murthy AK. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One. 2013; 8(5):e64917.
Score: 0.027
-
Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 2003 Jun; 3(6):801-9.
Score: 0.013